MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis we ...

The partnership will expand accessibility to Alberta Health-covered care, providing residents with access to licensed Alberta physicians virtually, from the location of their choice, with no user fees.Rocket Doctor’s platform will be tailored to Lethbridge County residents, supporting a wide range of needs including urgent care, chronic condition management / primary care, and mental health services.This collaboration addresses critical primary and urgent care gaps in rural communities, particularly for res ...

Marine brands again achieve 90%+ customer satisfaction in NMMA’s industry benchmark programChris-Craft adds 2026 Innovation Award for its reimagined Launch 27 EDEN PRAIRIE, Minn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Winnebago Industries (NYSE: WGO), a leading manufacturer of premium outdoor recreation products, today announced that its marine brands, Chris-Craft and Barletta Boats, have once again been recognized with Marine Industry Customer Satisfaction Index (CSI) Awards from the National Marine Manufactur ...

Holders of greater than 99% of the aggregate principal amount of the Existing Notes have already tendered and delivered their consents. Holders of greater than 99% of the aggregate principal amount of the Existing Term Loans have already agreed to participate in the Term Loans Transactions. ST. LOUIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage Solutions”), a leading provider of business solutions to consumer goods manufacturers and retailers, today announced the ear ...

MCDONALD, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Amaero Ltd (ASX:3DA) (OTC: AMROF) (“Amaero” or the “Company”), a leading U.S. domestic producer of high-value refractory and titanium alloy powders for additive and advanced manufacturing of components utilized by the defense, space, and aviation industries, is pleased to advise that it has entered into a scheme implementation deed (“SID”) with Amaero Inc. (a newly-formed Delaware corporation) (“Amaero US HoldCo”) to pursue a re-domiciliation of Amaero and ...

Core Viewpoint - Aktis Oncology, Inc. has received Fast Track designation from the U.S. FDA for its drug AKY-1189, aimed at treating adult patients with locally advanced or metastatic urothelial cancer who have progressed after prior systemic therapies [1][7] Group 1: Fast Track Designation - Fast Track designation is intended to expedite the development and review of drugs for serious conditions, allowing for more frequent interactions with the FDA and the possibility of rolling submissions for Biologics License Applications [2] - The designation provides Aktis Oncology a unique opportunity to collaborate closely with the FDA to expedite the development of AKY-1189, addressing an unmet medical need in urothelial cancer treatment [3] Group 2: Clinical Trials and Development - Aktis is conducting a multi-site Phase 1b clinical trial (NCT07020117) for AKY-1189, which includes patients with locally advanced or metastatic urothelial cancer and other Nectin-4 expressing tumors [3] - Preliminary results from Part 1 of the trial are expected to be presented in the first quarter of 2027 [3] Group 3: Technology and Pipeline - Aktis has developed a proprietary miniprotein radioconjugate platform that selectively delivers radioisotopes to targeted tumors, maximizing anti-cancer activity while minimizing exposure to normal tissues [4] - The company’s pipeline includes AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, with potential applications across various tumor types [5]

Core Insights - Artiva Biotherapeutics has appointed Thad Huston as Chief Financial Officer, bringing extensive experience in capital allocation and operational execution to support the company's growth in cell therapies for autoimmune diseases and cancers [1][2]. Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing safe and effective cell therapies for patients with autoimmune diseases and cancers [1][6]. - The company's lead program, AlloNK, is an allogeneic NK cell therapy designed to enhance the efficacy of monoclonal antibodies for B-cell depletion [6]. Leadership Appointment - Thad Huston has over 30 years of global leadership experience in finance, commercial strategy, and operations within the pharmaceuticals and biotechnology sectors [2]. - Huston previously served as CFO and COO at Galapagos, leading the company's transition to an oncology-focused cell therapy organization [2]. Inducement Grant - Artiva's Board of Directors approved an employment inducement grant of 220,000 restricted stock units to Mr. Huston, which will vest over four years [3][4]. - The grant is contingent upon the filing of a registration statement to register the shares under Artiva's 2025 Inducement Plan [4][5]. Clinical Development - AlloNK is currently being evaluated in three clinical trials targeting B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren's disease [6]. - The company is preparing to receive feedback from the FDA regarding a potential pivotal trial and plans to share clinical efficacy data in rheumatoid arthritis in the first half of the year [2]. Strategic Positioning - Artiva aims to position itself for sustained growth by leveraging Huston's financial discipline and operational rigor as it approaches key clinical and regulatory milestones [2].

Company strengthens industry-leading compliance program with new per-transaction identity verification procedure, enhancing protections against Crypto ATM fraudATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bitcoin Depot (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced it has initiated a phased rollout of a new compliance enhancement requiring customers to provide identification for every transaction at its kiosks, strengthening the Company’s safeguards again ...

KUALA LUMPUR, Malaysia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sagtec Global Limited (NASDAQ: SAGT), an AI-native enterprise SaaS provider, today announced a major strategic evolution of its technology stack: the deployment of an Agentic AI Orchestration Layer. This transition moves SAGT beyond traditional SaaS toward a fully Autonomous Agent model, designed to maximize AI ROI for its 12,000+ business clients. Following the success of its recent US$4.0 million Smart AI mobility contract, Sagtec is now integratin ...

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will parti ...